Prediction of chemotherapy response with platinum and taxane in the advanced stage of ovarian and uterine carcinosarcoma: A clinical implication of in vitro drug resistance assay

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 4, 2010, Pages 358-363

  Matsuo, Koji ^a,c   Bond, Virginia K ^a   Im, Dwight D ^a,b   Rosenshein, Neil B ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MERCY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carcinosarcoma; Chemotherapy; Drug resistance assay; Ovary; Platinum; Taxane; Uterus

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; ARTICLE; ASSAY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT RESPONSE; UTERUS CARCINOMA; UTERUS SARCOMA; AGED; CANCER INVASION; CARCINOSARCOMA; DISEASE FREE SURVIVAL; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; UTERUS CANCER;

AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOSARCOMA; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; UTERINE NEOPLASMS;

EID: 77956625419     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181af30d3     Document Type: Article

References (28)

1. Mano MS, Rosa DD, Azambuja E, et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer. 2007;17:316-324.
2. Silasi DA, Illuzzi JL, Kelly MG, et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer. 2008;18:22-29.
3. Brown E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004;100:2148-2153.
4. Rutledge TL, Gold MA, McMeekin DS, et al. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006;100:128-132.
5. Leiser AL, Chi DS, Ishill NM, et al. Carcinosarcoma of the ovary treated with platinum and taxane: The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol. 2007;105:657-661.
6. Duska LR, Garrett A, Eltabbakh GH, et al. Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. Gynecol Oncol. 2002;85:459-463.
7. Bicher A, Levenback C, Silva EG, et al. Ovarian malignant mixed müllerian tumors treated with platinum-based chemotherapy. Obstet Gynecol. 1995;85: 735-739.
8. Sit AS, Price FV, Kelley JL, et al. Chemotherapy for malignant mixed Müllerian tumors of the ovary. Gynecol Oncol. 2000;79:196-200.
9. Lin JF, Slomovitz BM. Uterine sarcoma 2008. Curr Oncol Rep. 2008;10: 512-518.
10. National Comprehensive Cancer Network guidelines. Available at: Www. nccn.org/professionals/physician-gls/default.asp.
11. Naumann RW. Uterine papillary serous carcinoma: State of the state. Curr Oncol Rep. 2008;10:505-511.
12. Samson DJ, Seidenfeld J, Ziegler K, et al. Chemotherapy sensitivity and resistance assays: A systematic review. J Clin Oncol. 2004;22:3618-3630.
13. Eltabbakh GH, Piver MS, Hempling RE, et al. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol. 1998;70:392-397.
14. Mäenpää JU, Heinonen E, Hinkka SM, et al. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: A prospective randomized trial. Gynecol Oncol. 1995;57:294-298.
15. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst. 1990;82:582-588.
16. EDR Assay. Available at http://www.oncotech.com/.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
18. Brown E, Markman M. Tumor chemosensitivity and chemoresistance assays. Cancer. 1996;77:1020-1025. (Pubitemid 26080889)
19. Bellamy WT. Prediction of response to drug therapy of cancer: A review of in vitro assays. Drugs. 1992;44:690-708.
20. Von Hoff DD, Sandbach JF, Clark GM, et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst. 1990;82:110-116.
21. Von Hoff DD, Kronmal R, Salmon SE, et al. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer. 1991;67:20-27.
22. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumors-is there any alternative? Anticancer Drugs. 1997;8:541-548.
23. Weisenthal LM, Kern DH. Prediction of drug resistance in cancer chemotherapy: The Kern and DiSC assays. Oncology (Williston Park). 1991;5:93-103.
24. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
25. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 1990;9:1-19.
26. Tate Thigpen J, Blessing JA, DeGeest K, et al. Gynecologic Oncology Group. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: A Gynecologic Oncology Group study. Gynecol Oncol. 2004;93:336-339.
27. Mehta RS, Bornstein R, Yu IR, et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat. 2001;66:225-237.
28. Schrag D, Garewal HS, Burstein HJ, et al. ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays. American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004;22:3631-3638.